Latest News - Alnylam Pharmaceuticals
Top Corporates Hub
Alnylam Pharmaceuticals
Alnylam vs. Ionis: Here's the Better Bad-News Buy
10.10.2026 09:04
The sell-offs for both of these beaten-down biotech stocks appear to be overdone.
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
09.10.2026 16:55
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
Is Vertex Stock Worth More Than Its Competitors?
09.10.2026 15:36
Vertex Pharmaceuticals (VRTX) stock trades at 29.0 times earnings. That valuation prices the company higher than Regeneron and Incyte, two of its biotech peers. Vertex does generate the highest operating margin among its group of five companies, but its sales are growing more slowly than at three of the other four. So how much more are you paying for Vertex, and what do you get for it.
Alnylam Pharmaceuticals (ALNY) Stock Looks Pricey Despite A 51% Slide
09.10.2026 15:11
Alnylam Pharmaceuticals has seen a steep share price reset over the past year, which puts the focus squarely on whether the current valuation lines up with what the business earns. With recent legal scrutiny adding another layer of uncertainty, the key issue for investors is how much of that risk and opportunity is already reflected in the stock. The share price has fallen 50.9% over the past year, which raises the question of whether the current level now better reflects the company’s...
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
09.10.2026 14:53
Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
09.10.2026 13:37
VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
09.10.2026 12:31
argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth
08.10.2026 10:50
ALNY screens as decent value: peer-relative discount, strong growth and profitability, but leverage, dilution, and earnings volatility pose risks.
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth
08.10.2026 10:50
ALNY screens as decent value: peer-relative discount, strong growth and profitability, but leverage, dilution, and earnings volatility pose risks.
3 Great Healthcare Stocks To Own In October 2026
02.10.2026 13:12
Global bond markets have just steadied after a sharp sell off that pushed US borrowing costs to levels last seen in 2002, which keeps reliable cash generation and robust finances firmly in focus. That backdrop puts financially solid healthcare leaders, from drug developers to equipment makers, on many watchlists. This article walks through three stand out stocks from a curated healthcare shortlist that meet those quality filters. The three healthcare stocks highlighted next are only a...
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
29.09.2026 13:00
CAMBRIDGE, Mass., September 29, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA® (vutrisiran) ‘Play by Play,’ a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) and the care teams who support them. Through personal stories and expert perspectives, ‘Play by Play’ aims to help people recognize the symptoms of ATTR-CM earl
Alnylam Needs Stronger Amvuttra Execution To Justify More Upside
26.09.2026 06:06
Alnylam at its current ~$255 valuation leaves limited upside without stronger commercial execution, especially for AMVUTTRA. Learn why ALNY stock is a hold.
RNAi drug specialist ADARx raises $446M IPO
25.09.2026 00:36
ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
20.09.2026 01:01
Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk. Duri
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
18.09.2026 10:42
RNAi Therapeutics Expand on Precision Medicine Demand, Advanced Subcutaneous Delivery and Growing Rare Disease ApplicationsDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "RNA Interference Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global RNA Interference Therapeutics Market to Reach USD 31.4 Billion by 2035 The global RNA interference therapeutics market was valued at USD 4.2 billion in 2025 a
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript
17.09.2026 16:08
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control September 17, 2026...
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control - Slideshow
17.09.2026 12:59
2026-09-17. The following slide deck was published by Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
14.09.2026 13:11
Alnylam Pharmaceuticals, Inc. (ALNY) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany ParticipantsYvonne...
Here’s Why Alnylam Pharmaceuticals (ALNY) Declined
10.09.2026 11:44
American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
08.09.2026 11:55
Alnylam Pharmaceuticals, Inc. (ALNY) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 8:45 AM EDTCompany ParticipantsJohn Kennedy - Senior...